FR 901483Alternative Names: WF 11231A . HCl
Latest Information Update: 05 Jun 2001
At a glance
- Originator Fujisawa
- Class Small molecules
- Mechanism of Action DNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 05 Jun 2001 No-Development-Reported for Transplant rejection in Japan (Unknown route)
- 06 Mar 1996 New profile
- 06 Mar 1996 Preclinical development for Transplant rejection in Japan (Unknown route)